P/B
5,8
Bristol-Myers Squibb
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
$129.5B
Market Cap • 9/11/2026
1933
(93 years)
Founded
1952
(74 years ago)
IPO
NYSE
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
2,6
P/EBITDA
8,7
P/OCF
10,1
P/FCF
11,3
P/E
14
BVPS
10,9
EPS
4,5
Market Cap
Market Cap
129,5B
EV
161,6B
EV/Revenue
3,3
EV/EBITDA
10,8
EV/EBIT
13,8
Payout
Dividend Per Share
2,5
Dividend Yield
3,9%
Buyback Yield
0,1%
Total Yield
4%
Dividend Yield 5Y
4,3%
Payout
54,9%
Retained Earnings
20,3B
Profitability
Gross Margin
70,2%
EBITDA Margin
30,3%
EBIT Margin
23,8%
Net Margin
18,9%
D&A/EBITDA
17%
R&D/Revenue
26,1%
Capex/Revenue
2,7%
Capex/D&A
42,3%
Capex/OCF
10,5%
SBC/OCF
4,3%
% PPE
8,9%
% Goodwill
24,8%
ROE
46,6%
ROIC
15,2%
Growth
CAGR Revenue 5Y
2,1%
CAGR OCF 5Y
0,4%
Leverage
N.D./EBITDA
2,2
Debt/Equity
0%
Current Ratio
1,5
Quick Ratio
1,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!